Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.66 |
| ▸ | BRD4 | O60885 | 2/20 | 0.66 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.55 |
| ▸ | CDK4 | P11802 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 3/20 | 0.53 |
| ▸ | CCND2 | P30279 | 3/20 | 0.53 |
| ▸ | CCND3 | P30281 | 3/20 | 0.53 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18376655 | 0.91 | JAK2 (0.67) | JAK2BRD4FGFR4CDK4AURKA | |
| SCHEMBL18377076 | 0.90 | JAK2 (0.65) | JAK2BRD4FGFR4CDK4AURKA | |
| SCHEMBL1633192 | 0.89 | JAK2 (0.55) | JAK2BRD4FGFR4CDK4AURKA | |
| SCHEMBL1632085 | 0.85 | SMG1 (0.62) | JAK2BRD4FGFR4CDK4AURKA | |
| SCHEMBL1633935 | 0.85 | MAPK10 (0.62) | JAK2BRD4FGFR4CDK1CCNA2 | |
| SCHEMBL29575830 | 0.85 | JAK2 (0.66) | JAK2BRD4FGFR4CDK4AURKA | |
| SCHEMBL18377046 | 0.85 | BRD4 (0.63) | JAK2BRD4FGFR4CDK4AURKA | |
| SCHEMBL28676614 | 0.83 | JAK2 (0.61) | JAK2BRD4FGFR4CDK4AURKA | |
| SCHEMBL29846917 | 0.83 | JAK2 (0.70) | JAK2BRD4FGFR4CDK4AURKA | |
| SCHEMBL16514362 | 0.83 | JAK2 (0.70) | JAK2BRD4FGFR4CDK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | JAK2 1352/4885BRD4 268/4885FGFR4 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.